The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid. The approval is based on results from the pivotal ADEPT phase 2/3 ...

A CDC report set to be presented on June 26 at a meeting of the agency's Advisory Committee on Immunization Practices finds ...

SNY trades below key moving averages but strong Dupixent growth, pipeline wins and rising estimates may keep bulls invested.

New York-based Formation Bio, an AI-native pharma company focused on accelerating drug development, revealed that its ...

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi will explore additional indications for gusacitinib in a Phase I study.

How TIME and Statista Determined the World's Most Sustainable Companies of 2025 In the fight against climate change, ...

The global allergic rhinitis market is poised for substantial growth from 2025 to 2035, driven by a rise in allergic diseases, and advancements in th ...

NEW YORK, NY, USA I June 23, 2025 I Formation Bio, an AI-native pharma company focused on accelerating drug development, today announced that its subsidiary ...